HTR3E
5-hydroxytryptamine receptor 3E
As of the edition of 20 October 2026, HTR3E (5-hydroxytryptamine receptor 3E, UniProt A5X5Y0) has 9 drugs tested at it and 9 companies on the list, 1 on route A and 0 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- A5X5Y0
- How well studied
- Chemical tools exist; no approved drug acts on it
- Where it sits in the cell
- At a membrane
- Disease areas
- Digestive system; Cancer; Mental health; Nervous system; Blood and lymph; Heart and blood vessels; Urinary and reproductive; Ear, nose and throat
- Registered trials of its drugs
- 86
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 2 |
| Active | 2 |
| Went quiet | 4 |
| Stopped | 1 |
| Total | 9 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Ramosetron | Marketed | Phase 4 | none listed |
| Mosapride | Active | Phase 4 | none listed |
| Tropisetron | Active | Phase 4 | none listed |
| Facinicline | Went quiet | Phase 2 | none listed |
| Pumosetrag | Went quiet | Phase 3 | none listed |
| RO5313534 | Went quiet | Phase 2 | none listed |
| Renzapride | Stopped | Phase 3 | none listed |
| Tedatioxetine | Went quiet | Phase 2 | none listed |
| Clothiapine | Marketed | No phase stated | none listed |
9 of 9 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 1 |
| Undetermined | 8 |
| Total on the list | 9 |
| Company | Route |
|---|---|
| Roche | Route A |
The other 8 companies at HTR3E
In the product9 companies in all; 8 are not named here, and no score is.
See the 9 companies at HTR3E, ranked, with the facts behind eachRequest access. Nothing is shown until you do.